- Home
- KIDS vs PBYI Comparison
KIDS vs PBYI Comparison
Compare KIDS & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIDS | PBYI |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.4M | 413.3M |
| IPO Year | 2016 | 2011 |
Fundamental Metrics
Financial Performance| Metric | KIDS | PBYI |
|---|---|---|
| Price | $22.10 | $9.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $24.67 | N/A |
| AVG Volume (30 Days) | 178.5K | ★ 262.7K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | ★ $98,049,000.00 | $27,685,000.00 |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | ★ N/A | $117.38 |
| Revenue Growth | ★ 37.95 | N/A |
| 52 Week Low | $14.42 | $4.30 |
| 52 Week High | $26.74 | $9.74 |
Technical Indicators
Market Signals| Indicator | KIDS | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 56.97 |
| Support Level | $17.54 | $8.78 |
| Resistance Level | $26.74 | $9.45 |
| Average True Range (ATR) | 0.84 | 0.35 |
| MACD | -0.45 | -0.02 |
| Stochastic Oscillator | 7.14 | 57.59 |
Price Performance
Historical ComparisonAbout KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.